• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Adynxx

edit

Adynxx a biopharmaceutical company, develops pain management drugs. It offers AYX1, a drug candidate to prevent acute post-operative pain and its transition into chronic pain; and AYX therapeutic programs, including long-term relief treatments for mature chronic pain syndromes. The company was incorporated in 2007 and is based in San Francisco, California.

Recent Milestones

edit

• 
  Adynxx received $4.8M in Series A funding. (1/11/11)
  Posted 1/12/11 at 5:08am via onbiovc.com
• 
  Adynxx added Julien Mamet as Founder & Chief Scientific Officer & Board Director. (10/1/07)
  Posted 5/21/13 at 1:48pm
• 
  Adynxx added Julien Mamet as CEO. (1/1/07)
  Posted 5/21/13 at 1:55pm

Videos

Screenshots

edit

Sources

1. Adynxx, Inc.: Series A $4.8M (onbiovc.com) [edit]